Oxymorphone Urine Screen in Arizona

What this test measures

Oxycodone is a widely prescribed opioid pain medication, and oxymorphone is a related opioid that also appears as a metabolite of oxycodone. Screening for both, along with their metabolites, improves the chance of detecting recent use. The assay used for this test is designed to be more specific than broad opiate screens, which may not reliably detect synthetic or semisynthetic opioids.

The sample is urine, collected at a laboratory or collection site under standard procedures. An initial immunoassay provides a presumptive result, and a positive finding is typically confirmed with mass spectrometry or a similar technique. Detection windows vary by the amount used, how often it is used, and the person's metabolism.

A screening result is not a diagnosis and does not measure impairment. It reports whether the targeted compounds were present above the laboratory cutoff at the time of collection. A qualified healthcare provider or the requesting organization interprets the result with the appropriate context, and disclosing current prescriptions supports accurate review.